B2

Claim 38. (Amended) A method of inhibiting the effects mediated by PKA type Iα isozyme comprising administering to subject in need of said inhibition, the pharmaceutical composition of any of Claims 22, 23 or 24, so as to inhibit the localization of PKA type Iα isozyme with T cell receptor/CD3 complexes.

REMARKS

On page 2 of the Office Action, the Examiner has issued a Restriction Requirement under 35 U.S.C. § 121 to one of the inventions of the following groups:

Group I - Claims 22, 24, 35 and 38-39, drawn to pharmaceutical compositions and methods of inhibiting the effects mediated by PKA type Iα isozyme using a cAMP antagonist;

Group II - Claims 22, 25-27, 35-36 and 38-39, drawn to pharmaceutical compositions and methods of inhibiting the effects mediated by PKA type Iα isozyme using a ribozyme;

Group III - Claims 22, 28-29, 35 and 37-39, drawn to pharmaceutical compositions and methods of inhibiting the effects mediated by PKA type Iα isozyme using an antisense oligonucleotide;

Group IV - Claims 22, 30-35 and 38-39, drawn to pharmaceutical compositions and methods of inhibiting the effects mediated by PKA type Iα isozyme using a peptide; and

Group V - Claims 22-23, 35 and 38-39, drawn to pharmaceutical compositions and methods of using a cAMP analog.

Specifically, the Examiner states that each of the groups are unrelated to each other and have different modes of operation.

Accordingly, Applicants hereby elect the invention of Group I, i.e., Claims 22, 24, 35 and 38-39 with traverse with respect to Group V. Applicants respectfully submit that the inventions of Groups I and V are related since the cAMP analog of Group V is an example of the cAMP antagonist of Group I (see Claim 23). Thus, Applicants request withdrawal of the Restriction Requirment as between Groups I and V.

As to the non-elected Claims, these claims are hereby cancelled without prejudice to the filing of a Divisional Application(s) on the non-elected invention(s).

Further, Applicants hereby amend the generic claims such that they are directed solely to the elected invention.

The Examiner is invited to contact the undersigned at his Washington telephone number on any questions which might arise.

Respectfully submitted,

Gordon Kit
Registration No. 30,764

SUGHRUE, MION, ZINN,
MACPEAK & SEAS, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, D.C. 20037
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

Date: September 28, 2001

A P P E N D I X

Marked-up Version of Changes

IN THE CLAIMS:

The claims are changed as follows:

Claim 22. (Amended) A pharmaceutical composition useful for treating an immunosuppresive disease comprising (A) a pharmaceutically effective amount of [an inhibitor selected from the group consisting of] a cAMP antagonist[, a hammerhead ribozyme, a sequence specific antisense oligonucleotide and an anchoring disruption peptide], wherein said [inhibitor] cAMP antagonist selectively or specifically abolishes the function of cAMP dependent protein kinase (PKA) type Iα isozyme ($RI\alpha_2C_2$); and (B) a pharmaceutically acceptable adjuvant or filler.

Claim 38. (Amended) A method of inhibiting the effects mediated by PKA type Iα isozyme comprising administering to subject in need of said inhibition, the pharmaceutical composition of any of Claims 22, 23 or 24 [23-34], so as to inhibit the localization of PKA type Iα isozyme with T cell receptor/CD3 complexes.